| Name | Title | Contact Details |
|---|
Delphinus Medical Technologies, Inc. is an innovation leader in advanced ultrasound development, introducing a dynamic new technique to image the breast with the use of sound and water. Delphinus is committed to creating improved imaging methods that assist medical professionals to better define and diagnose breast disease, while establishing a better patient experience that can be available for all women, regardless of age, without the concern of radiation or pain. Headquartered in Plymouth, MI, Delphinus is the first company to design and manufacture a whole breast ultrasound system that utilizes a ring transducer to transmit and receive ultrasound signals. Known as SoftVue™, three critical sound characteristics are measured and refined through proprietary algorithms, advancing this technology far beyond traditional b-mode ultrasound. By collecting and defining reflection, sound speed, and attenuation data in a 360° orientation, data are gathered and reconstructed in tomographic coronal planes, providing an enriched image set presented for cross-sectional review. SoftVue has received FDA clearance for diagnostic imaging purposes and is not intended for use as a replacement for screening mammography. Delphinus was formed in 2010 as a spin-out of Karmanos Cancer Institute [KCI] in Detroit, MI. Created by Peter Littrup, MD of Karmanos and Neb Duric, PhD of Wayne State University Detroit, MI the SoftVue technology presents a new imaging paradigm in breast disease assessment. Karmanos Cancer Institute has served as a primary investigational site for case collection and clinical studies. Delphinus holds numerous patents and proprietary assets for its innovative and scientifically-advanced works and is poised to usher in a new era of breast imaging.
Founded in 2019, Zing Health Holdings Inc. is a groundbreaking tech-enabled insurance company making Medicare Advantage the best it can be for those 65 and over or with long-term disability. Zing Health`s community-based approach addresses social determinants of health to keep individuals and communities healthy and returns the physician and the member to the center of the healthcare equation. This gives each member personalized care and service tailored to their singular needs. Members also receive individualized assistance to make their transition to Zing Health as easy as possible, and have the ability to personalize their plans, access to facilities designed to help them better meet their healthcare needs, and a dedicated care team.
Acucela is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases impacting millions of individuals worldwide. Acucela currently has the following candidates in development with Otsuka Pharmaceutical: emixustat hydrochloride for GA associated with dry AMD based on Acucela’s proprietary visual cycle modulation; and OPA-6566 for ocular hypertension and glaucoma.
24 Hour Emergency Room is a Tomball, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Urban Health Plan is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Bronx, NY. To find more information about Urban Health Plan, please visit www.urbanhealthplan.org